Floatz logo

Rimiducid

B-Cell Neoplasm

M.D. Anderson Cancer CenterSmall moleculePhase 1/2Dormant
CCC
49/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
34/ 100
Competitive Position
95/ 100

Competitive context

48 Active assets in the B-Cell Neoplasm cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
University Hospital, Basel, Switzerland
Phase 2BB
Zanubrutinib
Curis, Inc.
Phase 2BB
PREDNISONE TABLETS
Curis, Inc.
Phase 2BB
Inno-206
Curis, Inc.
Phase 2BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Curis, Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

Rimiducid is also rated in:

myelodysplastic syndromeDormant
CCC
Indicative ·
51 / 100
View asset →
inborn error of immunityDormant
CCC
Indicative ·
50 / 100
View asset →
myeloproliferative neoplasmDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →